MX358447B - Anticuerpos anti-psgl-1 y usos de los mismos. - Google Patents

Anticuerpos anti-psgl-1 y usos de los mismos.

Info

Publication number
MX358447B
MX358447B MX2013014814A MX2013014814A MX358447B MX 358447 B MX358447 B MX 358447B MX 2013014814 A MX2013014814 A MX 2013014814A MX 2013014814 A MX2013014814 A MX 2013014814A MX 358447 B MX358447 B MX 358447B
Authority
MX
Mexico
Prior art keywords
antibodies
psgl
cells
polynucleotides
kits
Prior art date
Application number
MX2013014814A
Other languages
English (en)
Other versions
MX2013014814A (es
Inventor
Enenkel Barbara
Litzenburger Tobias
Singh Sanjaya
Bassarab Stefan
Garidel Patrick
Schott Heidrun
Original Assignee
Abgenomics Cooeperatief U A Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX358447(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenomics Cooeperatief U A Star filed Critical Abgenomics Cooeperatief U A Star
Publication of MX2013014814A publication Critical patent/MX2013014814A/es
Publication of MX358447B publication Critical patent/MX358447B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal que se une inmunoespecíficamente a PSGL-1 de humano, una composición farmacéuticamente que comprende el anticuerpo, un equipo que comprende el anticuerpo y el uso farmacéutica de la composición.
MX2013014814A 2011-06-13 2012-06-12 Anticuerpos anti-psgl-1 y usos de los mismos. MX358447B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496249P 2011-06-13 2011-06-13
PCT/US2012/042068 WO2012174001A1 (en) 2011-06-13 2012-06-12 Anti-psgl-1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2013014814A MX2013014814A (es) 2014-07-22
MX358447B true MX358447B (es) 2018-08-21

Family

ID=47357432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014814A MX358447B (es) 2011-06-13 2012-06-12 Anticuerpos anti-psgl-1 y usos de los mismos.

Country Status (20)

Country Link
US (4) US20130209449A9 (es)
EP (2) EP2718325A4 (es)
JP (1) JP6180408B2 (es)
KR (1) KR102103036B1 (es)
CN (3) CN116063522A (es)
AU (1) AU2012271845B2 (es)
BR (1) BR112013031892A2 (es)
CA (1) CA2838952C (es)
CL (1) CL2013003570A1 (es)
CO (1) CO6940376A2 (es)
EC (1) ECSP14013132A (es)
IL (2) IL229844B (es)
MX (1) MX358447B (es)
NZ (1) NZ619524A (es)
RU (1) RU2650817C2 (es)
SG (1) SG10201604767TA (es)
TW (1) TWI643872B (es)
UA (1) UA114712C2 (es)
WO (1) WO2012174001A1 (es)
ZA (1) ZA201400209B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
TWI454274B (zh) 2004-05-11 2014-10-01 Abgenomics Cooperatief Ua Ｔ細胞之死亡誘導表位
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
JP7240808B2 (ja) * 2014-07-08 2023-03-16 サンフォード バーナム プレビーズ メディカル ディスカバリー インスティテュート Ｐｓｇｌ－１モジュレーターおよびその使用
NZ743815A (en) 2016-01-08 2023-06-30 Altrubio Inc Tetravalent anti-psgl-1 antibodies and uses thereof
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
CN111201038A (zh) 2017-01-11 2020-05-26 戊瑞治疗有限公司 Psgl-1拮抗剂及其用途
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
US11603406B2 (en) 2017-03-14 2023-03-14 Five Prime Therapeutics, Inc. Antibodies binding to VISTA at acidic pH
CA3104536A1 (en) 2018-07-11 2020-01-16 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
CA3106418A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
CN114401990A (zh) * 2019-06-04 2022-04-26 维西欧制药公司 用于调节髓系细胞炎性表型的抗psgl-1组合物和方法及其用途
CN113667015B (zh) * 2021-08-20 2022-10-11 北京康特泊瑞生物医药科技股份公司 靶向psgl-1蛋白的抗体及其用途
CN118696059A (zh) * 2021-11-17 2024-09-24 美国全心医药生技股份有限公司 使用抗psgl-1抗体与jak抑制剂的组合治疗t细胞介导的炎症性疾病或癌症的方法
WO2024057232A1 (en) * 2022-09-13 2024-03-21 Tetherex Pharmaceuticals Corporation Antibodies, compositions, and methods of treatment

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
WO1993019180A1 (en) 1992-03-17 1993-09-30 Ciba-Geigy Ag Genetically engineered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
EP0689599B1 (en) 1993-01-25 1998-12-09 Dana-Farber Cancer Institute, Inc. Chimeric selectins by exchange of domains - uses thereof
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
MXPA98000968A (es) 1995-08-03 2002-07-15 Univ Oklahoma Peptido e inhibidores del o-glucano de la inflamacion mediada por selectina.
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
BR9914957A (pt) 1998-10-30 2001-07-24 Genetics Inst Inibição de células t citotóxicas por antagonistas de ligando de selectina-p (psgl)
DK2270150T4 (da) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
EP1289552B1 (en) 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
WO2002022820A1 (en) 2000-09-12 2002-03-21 Genetics Institute, Llc Inhibition of stenosis or restenosis by p-selectin antagonists
EP1406930A4 (en) 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"
US20040001839A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
CA2491363A1 (en) 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
WO2005005455A2 (en) 2003-06-30 2005-01-20 Bio-Technology General (Israel)Ltd. Specific human antibodies
BRPI0417266B8 (pt) * 2003-12-25 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo monoclonal, seu uso e composição farmacêutica
US7544487B2 (en) * 2004-02-13 2009-06-09 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic RNAses
ES2403055T3 (es) * 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
TWI454274B (zh) 2004-05-11 2014-10-01 Abgenomics Cooperatief Ua Ｔ細胞之死亡誘導表位
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
EP2644621B1 (en) * 2007-03-22 2017-12-13 Genentech, Inc. Apoptotic anti-IgE antibodies
ES2593484T3 (es) * 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
EP2164873B2 (en) * 2007-05-31 2018-09-12 Genmab A/S Stable igg4 antibodies
BRPI0812400A2 (pt) 2007-06-05 2014-10-29 Univ Yale Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
JP2010537985A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20110086366A1 (en) * 2008-02-22 2011-04-14 Genmab A/S Methods for assessing the risk of adverse events upon treatment with igg4 antibodies
US7833530B2 (en) * 2008-05-15 2010-11-16 Selexys Pharmaceuticals Corporation Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies
KR20110128923A (ko) * 2009-03-12 2011-11-30 이메드 아베 인간 ｆａｓ에 대한 인간 항체 및 그의 용도
CN102762593B (zh) * 2009-07-31 2015-05-20 梅达雷克斯有限责任公司 抗btla的完全人抗体
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
EP3157560A4 (en) 2014-06-20 2018-02-21 Abgenomics International Inc. Her2 antibody-drug conjugates

Also Published As

Publication number Publication date
RU2650817C2 (ru) 2018-04-17
KR102103036B1 (ko) 2020-04-22
EP2718325A4 (en) 2015-03-11
CL2013003570A1 (es) 2014-08-22
US20130251708A1 (en) 2013-09-26
ZA201400209B (en) 2020-05-27
EP3925978A1 (en) 2021-12-22
US20130011391A1 (en) 2013-01-10
TW201302791A (zh) 2013-01-16
IL287270A (en) 2021-12-01
CN103732626A (zh) 2014-04-16
WO2012174001A1 (en) 2012-12-20
MX2013014814A (es) 2014-07-22
IL229844B (en) 2022-02-01
US20210395383A1 (en) 2021-12-23
US20240124604A1 (en) 2024-04-18
JP6180408B2 (ja) 2017-08-16
JP2014519524A (ja) 2014-08-14
CA2838952C (en) 2020-11-24
CA2838952A1 (en) 2012-12-20
US20130209449A9 (en) 2013-08-15
ECSP14013132A (es) 2015-04-30
BR112013031892A2 (pt) 2016-11-22
TWI643872B (zh) 2018-12-11
CN116063522A (zh) 2023-05-05
US11897964B2 (en) 2024-02-13
CN108892726A (zh) 2018-11-27
AU2012271845A1 (en) 2014-01-23
RU2013158083A (ru) 2015-09-20
KR20140066153A (ko) 2014-05-30
EP2718325A1 (en) 2014-04-16
SG10201604767TA (en) 2016-08-30
UA114712C2 (uk) 2017-07-25
NZ619524A (en) 2016-10-28
AU2012271845B2 (en) 2017-07-27
CO6940376A2 (es) 2014-05-09

Similar Documents

Publication Publication Date Title
MX358447B (es) Anticuerpos anti-psgl-1 y usos de los mismos.
MY171038A (en) Bispecific antigen binding molecules
MY169358A (en) Bispecific t cell activating antigen binding molecules
MX2020009692A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
PH12016502505A1 (en) Bispecific t cell activating antigen binding molecules
MX2015010843A (es) Moleculas biespecificas de union al antigeno que activan celulas t.
MX2015010350A (es) Moleculas de union a antigeno biespecificas que activan la celula t.
PH12017500939A1 (en) T cell activating bispecific antigen binding molecules agiant folr1 and cd1
MX2018003631A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
MX2017006626A (es) Cadenas ligeras comunes y metodos de uso.
PH12014501108A1 (en) Anti-il-36r antibodies
MX2014008963A (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
SG194465A1 (en) Novel immunoconjugates
UA116766C2 (uk) Зв'язувальна молекула, яка є біоспецифічною до вcma і cd3
MX359854B (es) Anticuerpos anti-cxcr3.
MX349662B (es) Anticuerpos de antigenos antitumorales y metodos de uso.
MX360620B (es) Anticuerpos anti kit y usos de los mismos.
EA201391585A1 (ru) Терапевтические нуклеазные композиции и способы
MX358991B (es) Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
EA201590148A1 (ru) Генетически модифицированные микроорганизмы, способные продуцировать бета-глюканы, и способ получения бета-глюканов
TN2013000265A1 (en) Anti-cd38 antibodies
TH157671A (th) แอนติ-psgl-1 แอนติบอดีและการใช้ของมัน

Legal Events

Date Code Title Description
FG Grant or registration